Psychiatric Services
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Psychiatr Serv 60:1466-1467, November 2009
doi: 10.1176/appi.ps.60.11.1466
© 2009 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
Google Scholar
* Articles by Insel, T. R.
* Articles by Wang, P. S.
PubMed
* PubMed Citation
* Articles by Insel, T. R.
* Articles by Wang, P. S.
Related Collections
* Depression
* Antidepressants
*Related Article

Special Section on the Implications of STAR*D

The STAR*D Trial: Revealing the Need for Better Treatments

Thomas R. Insel, M.D. and Philip S. Wang, M.D., Dr.P.H.

Dr. Insel is director and Dr. Wang is deputy director of the National Institute of Mental Health, 6001 Executive Blvd., Rm. 8235, MSC 9669, Bethesda, MD 20892-9669 (e-mail: insel{at}mail.nih.gov). This commentary is part of a special section on the STAR*D trial (Sequenced Treatment Alternatives to Relieve Depression) and the implications of its findings for practice and policy. Grayson S. Norquist, M.D., M.S.P.H., served as guest editor of the special section.

STAR*D (Sequenced Treatment Alternatives to Relieve Depression) continues to stimulate debate. The landmark trial demonstrated the feasibility of large-scale, community-based studies conducted without pharmaceutical company support. The results provided insight into nonresponse to initial treatment with selective serotonin reuptake inhibitors and alternatives for second- and third-line treatment options and suggested opportunities for personalized approaches to depression care. However, initial and one-year remission rates (28% and 70%, respectively) suggest that important goals for treatment of this disabling disease remain out of reach and that the bar for antidepressants has been set far too low.


Related Article:

November: This Month's Highlights
Psychiatr Serv 2009 60: 1425. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Psychiatr. Serv.Home page
G. S. Norquist
Introduction to the STAR*D Special Section
Psychiatr Serv, November 1, 2009; 60(11): 1437 - 1438.
[Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2009 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org